BHC - Why Bausch Health Stock Plunged After Posting First-Quarter 2024 Results
2024-05-07 09:15:00 ET
Summary
- Bausch Health Companies stock experienced a significant drop after posting its first-quarter results, missing expectations by 13 cents.
- The company's debt maturity profile raises concerns for investors, with a large amount of debt maturing in 2025 and even more in 2027-2028.
- Despite the challenges, Bausch Health sees opportunities for growth, particularly in its Xifaxan product and Solta Medical unit, and has issued a full-year revenue target of $4.70 billion to $4.85 billion.
- BHC stock's grades discussed.
Ahead of posting its first-quarter results , Bausch Health Companies Inc. ( BHC ) reached a 52-week high in the last month. Bargain hunters who bought the stock since last Nov. 2023 did not expect the stock to lose 15.3% in only a week and 27.76% in a month. The stock’s uptrend showed a positive slope on the 50-day and 200-day moving averages....
Why Bausch Health Stock Plunged After Posting First-Quarter 2024 Results